| 产品描述: | TAS-119 是一种有效的,选择性的,具有口服活性的 Aurora A 抑制剂,IC50 为 1.0 nM。TAS-119 对 Aurora A 的选择性高于其他蛋白激酶,包括 Aurora B (IC50 为 95 nM)。TAS-119 具有有效的抗肿瘤活性。 |
| 靶点: |
Aurora A:1 nM (IC50);Aurora B:95 nM (IC50) |
| 体外研究: |
TAS-119 enhances the antiproliferative effect of Paclitaxel in a variety of human cancer cell lines, including Paclitaxel-resistant cells. TAS-119 (30-300 nM) dose dependently enhances cell growth inhibition by three taxanes (Paclitaxel, Docetaxel, and Cabazitaxel) in HeLa cells. TAS-119 induces mitotic accumulation predominantly in tumor cells, compared with that in normal diploid fibroblasts. |
| 体内研究: |
TAS-119 (5-30 mg/kg; oral administration; twice daily on day 1 and everyday on day 2) treatment induces phosphorylated histone H3 (pHH3) in nude rats with the HeLa-luc xenografts. |
| 参考文献: |
1. Hiroshi Sootome, et al. Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design. Mol Cancer Ther. 2020 Oct;19(10):1981-1991. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.975 ml |
9.874 ml |
19.749 ml |
| 5 mM |
0.395 ml |
1.975 ml |
3.95 ml |
| 10 mM |
0.197 ml |
0.987 ml |
1.975 ml |
| 50 mM |
0.039 ml |
0.197 ml |
0.395 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |